Hybrid Media: Examines Pancreatic Cancer and Oil Spills Two Years After The BP Disaster

Robert Graham Reporting From OTC Offshore Technology Conference Houston, Texas April 30, 2012 A Interview with Rose Conrad GenNXeix Biotech Inc C.E.O

---

Hybrid Media: Examines Pancreatic Cancer and Oil Spills Two Years After The BP Disaster

---

All Workers Exposed To The BP Disaster should get a Genomics Test for Pancreatic Cancer says Rose Conrad Ph.D. Gennxeix Biotech researchers can compare normal and tumor DNA has shown that the gene for a subunit of the multi-subunit SWI/SNF protein complex was either deleted, mutated or rearranged in about a third of the 70 human pancreatic cancers from the region

that the GenNXeix team examined. Gennxeix researchers found that restoring the expression of one of the missing genes slowed the growth of pancreatic cancer cells. The pancreatic cancer enter a state called senescence. "This is really strong genetic evidence that this complex plays a role in pancreatic cancer, and it suggests the influence of the SWI/SNF complex is on par with that of other well-known tumor suppressors, such as p53. The tumor-suppressing role of the SWI/SNF complex We should not that, one person's pancreatic cancer might have a mutation or deletion in one protein subunit, while another's could have a change in a different subunit. Gennxeix used a array comparative genomic hybridization, or CGH, to pinpoint places in the genome that differed among normal and

cancerous pancreatic epithelial cells. The procedure relies on the ability of single-stranded DNA to seek out and bind to its mirror image. By comparing the relative amounts of tumor and normal DNA that bind to a panel of reference sequences, the researchers can tell whether the cancer cell contains amplifications or deletions of genetic material in specific regions throughout the genome. These copy-number variations often occur in genes or regions important in regulating uncontrolled cell growth. The researchers examined about 35 different pancreatic cancers, . 24 of the cancers were primary samples from human patients that had been asked to grow in immune-deficient mice; 11 had been maintained as laboratory-grown cancer cell lines. Gennxeix used high-density arrays of reference DNA sequences for the CGH, which allowed the identifi mplified or deleted regions at a much higher resolution than previously possible -- narrowing the areas of interest to just a few

thousand nucleotides rather than larger stretches of DNA. GeNnxeix looked at the results of the array CGH analysis, and observed that genes known to be involved in pancreatic cancer, and also some new candidates. In particular, they noticed that the genes for individual subunits of the SWI/SNF complex were altered in about 5 to 10 percent of the cancer samples -- an interesting finding, but not prevalent enough to spark further immediate investigation under normal circumstances. realized that more than a third of the cancer samples contained a deletion, mutation or rearrangement in the genes.

Our Genes Can Not Be Patent Protected All Breast Cancer Scientist Is Free To Develop a Cure

Robert Graham Reporting From Supreme Court Washington DC. April 25, 2012 Our Genes Can Not Be Patent Protected All Breast Cancer Scientist Is Free To Develop a Cure Kudos To The Supreme Court For Fixing Case Number 10-1150 Mayo Collaborative Services v. Prometheus

Laboratories......... Breast Cancer Patients Can Now Benefit From Every Scientist In The World Working On A Cure @GenNXeix Biotech Our Science NoteBook is BRCA1 BRCA2 Compliant Gennxeix Biotech is clear to sale it's Science NoteBook to Breast Cancer Doctors. Now that the Supreme court has ruled on Myriad Genetics Inc case. The is patent protection, Patent protection is important for companies that are focusing on personalized medicine, including Gennxeix Myriad Genetics Inc. (MYGN) and Novartis AG. (NOVN) The field involves determining whether a patient is genetically susceptible to a particular disease or would be especially responsive to certain medicine. On 26 March, the US Supreme Court handed down a short summary disposition as the latest instalment in a

long-running case that questions whether human genes can be patented. The Court simply vacated the 2011 decision by the Court of Appeals for the Federal Circuit (CAFC), which upheld Myriad Genetics Inc's (Myriad) patents relating to the BRCA genes, and sent the case back down to the CAFC for rehearing in light of a Supreme Court case on patenting laws of nature, handed down just six days earlier (Mayo Collaborative Services v Prometheus Laboratories, 10-1150) (Mayo). The History of. Case 10-1150 In 2009, the Association for Molecular Pathology together with many others filed suit against Myriad, the US Patent Office, and others, seeking to overturn 15 claims in seven of Myriad’s patents. The patents at

issue relate to both process claims (method for detecting increased risk of breast cancer) and composition-of-matter claims (the BRCA1 and BRCA2 isolated genes). In 2010, Judge Sweet in the US District Court (SDNY) held that both the genes and methods were not patentable. In relation to the genes, they were not ‘markedly different’ to naturally occurring genes. Myriad’s argument that the technique of purifying the genes rendered the compounds patent-eligible was rejected. Judge Sweet noted the dual nature of genes as both compositions of matter and carriers of information. The fact that, even after the purification process, the information provided by the genes remained the same meant that they were unpatentable products of nature. As for the method claims, Judge Sweet relied on a ‘machine or transfer’ (MOT) test developed in an earlier CAFC decision (Bilski v Kappos) to conclude that the claims to the process of analysis or comparison in the technique were no more than ‘abstract mental processes’. However, the Supreme Court later qualified the CAFC opinion, leaving this aspect of Judge Sweet’s opinion particularly vulnerable to appeal. Unsurprisingly Myriad appealed, and last year the CAFC overturned parts of the first instance decision, finding that because isolated DNA had been ‘cleaved’ (covalent bonds in its backbone chemically severed) it was rendered a different molecule, just a fraction of a native DNA molecule, and thus patentable. However, on the method claims the CAFC largely upheld the prior decision, invalidating all claims except one on the basis that they were merely abstract mental processes. The surviving method claim was directed to a method for screening potential cancer therapies. This claim included a transformative step, satisfying the MOT test. How much guidance the Mayo case can provide for the CAFC, given that it deals with process patenting, rather than compositions of matter. In Mayo, the Supreme Court found that a process for determining dosages for a person with auto-immune disease was unpatentable. The relationship between certain concentrations of metabolites in a patient’s blood and the likelihood of under or over-dosing were merely laws of nature. Accordingly, the claimed processes were unpatentable unless they contained steps that genuinely applied the laws of nature, rather than merely constituting an attempt to monopolise the natural correlation itself. The additional steps in the claims did not transform an unpatentable law of nature into a patent-eligible application. Myriad will now have to wait for the CAFC to consider and apply the ramifications of Mayo, and decide on the composition of matter issue – probably late 2012 or 2013. For this reason, some analysists are predicting the CAFC may well uphold Myriad’s composition claims. In any event, Myriad has a suite of other patents protecting its BRACAnalysis technique which would likely deter others from its use, at least in the short term. So Myriad remains bullish on the issue, stating that it will ‘vigorously defend’ its claims because of their ‘great importance to the medical, pharmaceutical, biotechnology and other commercial industries’. Life Science Companies are free to find A Cure for Breast Cancer using Genomics.

The Genomic Revolution is A Live at The New Methodist Hospital Houston

Robert Graham Hybrid Medical Media Reporting From The ACRP 2012 Global Conference Houston, Texas April, 16 2012

The Genomic Revolution is A Live at The New Methodist Hospital Houston

Genomics is marking a mark in Houston speaking with Kelly J. Maresh RN, MBA ACRP 2012
Global Conference Houston. The Methodist Hospital Research Institute has identified more than 500 genes that may cause or contribute to the development of pancreatic cancer. This particularly deadly disease has a 1-in-20 survival rate after five years, largely because no effective genetic screening method exists for early detection.

Principal investigators Nancy Jenkins, Ph.D., and Neal Copeland, Ph.D., report in
ftPJhe Proceedings of the National Academy of Sciences, that the vast majority of the 543 genes they identify in mouse models have identical or highly similar versions in humans, and that 20 of those equivalent genes were found to be strongly associated with poor survival in human pancreatic cancer patients.

"Knowing what genes are involved in the development of pancreatic cancer, as well as what those genes' functions are and how they influence signaling pathways, will be crucial to the development of new drugs and other therapies," said Copeland, director of The Methodist Hospital Research Institute Cancer Research Program and a National Academy of Sciences fellow.


A success story at Methodist Hospital Houston is The Methodist Academy. The Methodist Academy is a scholarly partnership between The Methodist Hospital Research Institute, Weill Cornell Medical College, and the Weill Cornell Graduate School of Medical Sciences of Cornell University. It is governed by the Council of Deans, which includes members of the Institute of Medicine, National Academy of Science, and National Academy of Engineers.

The purpose of The Methodist Academy is to develop educational and research partnerships that foster medical innovation. These partnerships will expand to include additional partner institutions and train students and postdoctoral researchers to be leaders of medicine by identifying clinically relevant challenges, and developing research programs that translate into technological advances in the clinic.

ACRP 2012 has the worlds Best Group Of Clinical Research Organization Collaborating, Networking using Genomic Science. GenNXeix Biotech has agreed to Join ACRP

Breast Cancer and HIF-1 Is Why ObamaCare Must Stay in Place

Robert Graham and Hybrid Medical Media Reporting from Chicago American Association Cancer Research April, 2012-------

Breast Cancer and HIF-1 Is Why ObamaCare must stay in place. To stop breast cancer from spreading to the patients lungs. Breast cancer spreading to the lungs is the number one reason breast cancer patients expire. Primary Care Physicians and Obama Care is key to prevent women expiring from breast cancer and extend their life.

Gennxeix Biotechnology Scientist Using Genomics has made progress in Houston working with HIF-1. Hypoxia-inducible factor 1 (HIF-1) is a transcriptional activator for breast cancer. Advances in biochemical purifica- tion, molecular characterization and cellular - molecular biol- ogy ofHIF-1. Gennxeix found involvement in human breast cancer progression, based on the analysis of human breast cancer biopsies and experimental animal mice models. HIF-1 as a therapeutic target can extend the life of many stage four breast Cancer patients.
Gennxeix discovered The tumor suppressors VHL (von Hippel-Lindau protein) and p53 target HIF-1α for ubiquitination to inactivation breast cancer tumors cells increases the of HIF-1. This process Increased phosphatidylinositol 3-kinase (PI3K) and AKT. In breast cancer, increased activity of the HER2 (also known as neu) receptor tyrosine kinase is associated with increased tumor grade, chemotherapy resistance, and decreased patient survival. HER2 has also been implicated as an inducer of VEGF expression. GenNXeix demonstrate that HER2 signaling induced by overexpression in mouse 3T3 cells or human MCF-7 breast cancer cells results in increased HIF-1α protein and VEGF mRNA expression that is dependent upon activity of PI3K, AKT (also known as protein kinase B), and the downstream kinase FRAP (FKBP-rapamycin-associated protein)
Gennxeix concern with patients with diabetes and breast cancer may not receive full Benefit of HIF-1. All women having access to a physician can have access to HIF-1.
Genomics provide a faster cheaper more effective way to detecting Breast Cancer by using Semiconductor Sequencing. A example of this technique is Gennxeix Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.
A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Gennxeix also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Gennxeix. computer-assisted diagnosing of breast cancer from mammograms. Gennxeix works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Gennxeix uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Gennxeix's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.
Gennxeix used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

Genomics can be the GPS to Extend life in Breast Cancer Patients.

Sent from my BlackBerry® wireless handheld